Page 1

August 10 , 2021 Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2021 Financial Results NEW YORK , Aug. 10 , 2021 / PRNewswire / -- Relmada Therapeutics , Inc. ( Nasdaq : RLMD ) , a late - stage biotechnology company addressing diseases of the central nervous system ( CNS ) , today provided a corporate update and announced financial results for the three and six months ended June 30 , 2021 . B Relmada THERAPEUTICS " The multiple clinical studies that comprise RELIANCE , the pivotal Phase 3 program for REL - 1017 as a potential adjunctive treatment for the treatment of major depressive disorder ( MDD ) , continue to progress , " said Sergio Traversa , Relmada's Chief Executive Officer . " The program was further advanced with the clear results of the human abuse potential ( HAP ) study that reenforced the safety findings of the clinical program to date , establishing a highly statistically significant separation from the active control . Looking ahead , we anticipate multiple key data readouts over the next 12 months , and have added a potential long - term growth driver with the acquisition of development and commercial rights to a novel psilocybin and derivate program . Importantly , our robust R & D initiatives are supported by a strong balance sheet . " Recent Corporate Highlights • Announcement of top - line results of the HAP study comparing REL - 1017 to oxycodone and placebo , confirming the absence of any meaningful opioid abuse liability of REL- 1017 . • Acquisition of development and commercial rights to a novel psilocybin and derivate program from Arbormentis LLC in all ex - Asia territories , including the U.S. and Europe focusing on neurodegenerative disorders . • Presentation of three posters highlighting preclinical and clinical data for REL - 1017 at the College on Problems of Drug Dependence 83rd Annual Meeting , and the 2021 American Society of Clinical Psychopharmacology Annual Meeting . Second Quarter 2021 Financial Results • Research and development expenses for the second quarter ended June 30 , 2021 , totaled $ 17.3 million , compared to $ 5.3 million in the second quarter ended June 30 , 2020. The increase was primarily driven by increased costs associated with preparing and conducting RELIANCE , the Company's Phase 3 program for REL - 1017 .